Table 5:
Multivariable Logistic Regression Associations of Potential Predictors of 50% Reduction Fecal Incontinence Episodes Treatment Response (5a) and Controlling for Adherence at 24 Weeks (5b)
| 5a: Predictor Variable | Overall p value for predictor | Odds Ratio Point Estimate | Lower 95% CL | Upper 95% CL | P value for OR | P value for treatment x predictor interaction |
|---|---|---|---|---|---|---|
| Treatment Randomization | 0.01 | |||||
| Loperamide/Biofeedback vs. Control1 | 4.04 | 1.36 | 11.98 | 0.01 | ||
| Loperamide/Education Only vs. Control1 | 0.68 | 0.27 | 1.76 | 0.43 | ||
| Placebo/Biofeedback vs. Control1 | 1.88 | 0.69 | 5.11 | 0.22 | ||
| Prior Rectal Surgery: No vs. Yes | 0.17 | 0.49 | 0.18 | 1.37 | 0.17 | 0.97 |
| Average Leaks/Week | 0.19 | 1.02 | 0.99 | 1.06 | 0.19 | 0.41 |
| St. Mark’s Score | 0.05 | 0.04 | ||||
| In Loperamide/Biofeedback Group | 0.88 | 0.72 | 1.06 | 0.18 | ||
| In Loperamide/Education Only Group | 1.02 | 0.90 | 1.16 | 0.73 | ||
| In Placebo/Biofeedback Group | 1.16 | 1.00 | 1.34 | 0.05 | ||
| In Control Group | 1.29 | 1.01 | 1.65 | 0.045 | ||
| MMHQ Severity Score | 0.88 | 1.00 | 0.99 | 1.02 | 0.88 | 0.14 |
| Fecal Incontinence - Leak Type | 0.01 | 0.67 | ||||
| Urge vs. Both | 2.39 | 1.09 | 5.25 | 0.03 | ||
| Passive vs. Both | 3.26 | 1.48 | 7.17 | <0.01 |
| 5b:Predictor Variable | Overall p value for predictor | Odds Ratio Point Estimate | Lower 95% CL | Upper 95% CL | P value for OR |
|---|---|---|---|---|---|
| Treatment Randomization | 0.04 | ||||
| Loperamide/Biofeedback vs. Control | 4.18 | 1.11 | 15.78 | 0.03 | |
| Loperamide/Education Only vs. Control | 0.76 | 0.30 | 1.91 | 0.55 | |
| Placebo/Biofeedback vs. Control | 1.75 | 0.49 | 6.22 | 0.39 | |
| Prior Rectal Surgery: No vs. Yes | 0.14 | 0.46 | 0.16 | 1.29 | 0.14 |
| Average Leaks/Week | 0.32 | 1.02 | 0.99 | 1.05 | 0.32 |
| St. Mark’s Score2 | 0.11 | 1.07 | 0.99 | 1.17 | 0.11 |
| MMHQ Severity Score | 0.88 | 1.00 | 0.99 | 1.01 | 0.88 |
| Fecal Incontinence - Leak Type | 0.02 | ||||
| Urge vs. Both | 2.20 | 1.00 | 4.85 | 0.05 | |
| Passive vs. Both | 3.02 | 1.38 | 6.62 | <0.01 | |
| Drug Adherence (last time drug was missed) at 24 Weeks | 0.94 | ||||
| Within the past week vs. Never missed | 0.81 | 0.35 | 1.86 | 0.62 | |
| 1–4 weeks vs. Never missed | 1.00 | 0.40 | 2.52 | 1.00 | |
| Greater than 1 month vs. Never missed | 0.83 | 0.36 | 1.90 | 0.65 | |
| Exercise Adherence (last time exercise was missed) at 24 Weeks | 0.36 | ||||
| Within the past week vs. Never missed | 1.07 | 0.34 | 3.36 | 0.91 | |
| 1–4 weeks vs. Never missed | 0.47 | 0.11 | 1.98 | 0.30 | |
| Greater than 1 month vs. Never missed | 2.32 | 0.38 | 14.32 | 0.36 |
1
Odds ratios for treatment groups were evaluated at the mean baseline St. Mark’s score of 14.2
2
The interaction between treatment group and baseline St. Mark’s score was not statistically significant in the model controlling for treatment adherence and was not included in the final model